Type 2 Diabetes
BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Published in Medical Letter on the CDC and FDA, November 22nd, 2009
Amylin Pharmaceuticals, Inc., (NASDAQ:AMLN) and Eli Lilly and Company (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA=AE (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for use only in patients who were also taking other common diabetes medications and had not achieved adequate glycemic control.
"The expanded indication gives physicians the option to prescribe BYETTA as a first-line treatment, increasing the number of patients who may...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Cincinnati Children's Hospital Medical Center
Pandemic flu vaccine campaigns may be undermined by coincidental medical events - Autism Research Institute
Chelation Therapy Drug Found Safe and Beneficial for Children With Autism - Cephalon, Inc.
Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder - Consumer Reports
Consumer Reports: Tests Find Wide Range of Bisphenol a in Canned Soups, Juice, and More - ERYtech Pharma
ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board - Implants
Third Annual Review of the National ICD Registry Now Available - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
